1. Introduction
Chronic obstructive pulmonary disease (COPD) has been considered a significant global health issue, with increasing prevalence causing a substantial burden of disease for those infected and on society [1]. Furthermore, the growth of the prevalence and burden of COPD has been predicted to be on the rise, as a result of the hardly changing popularity of smoking, increasing air pollution and general aging of the world population [2]. According to recent projections, COPD will become the third leading cause of death and the seventh leading cause of disability-adjusted life years (DALYs) worldwide by 2030, exhibiting a major increase in terms of mortality and DALY-caused rankings in 1990, which were sixth and twelfth, respectively [3]. COPD-induced deaths have been particularly high in low and middle-income countries (LMICs), accounting for more than 90% of the total COPD fatalities worldwide [1], signaling that possibly more attention and effort should be placed on COPD prevention and control in these regions.
Despite becoming a rising global health threat, COPD has still largely been regarded as a preventable and treatable health problem [2]. Recommended strategies for COPD management commonly involve the use of inhaled medication [4]. It has been generally accepted that delivering medications via inhalation would allow for accurate and direct administration of medications to the intended area, while systemic absorption would be reduced, which in turn increases the possibilities of clinical benefit utilization and decreases the risk of potential side effects [5]. However, a number of studies have indicated that such COPD management strategies have not succeeded in providing optimal efficiency, with medication non-adherence and incorrect inhaler technique found in patients being cited as the main reasons [4,6,7]. Understanding the barriers to optimal inhaler use among patients as well as determining solutions to overcome these obstacles can be said to be essential to enhancing the effectiveness of COPD treatment.
Although the prevalence and severity of COPD in Vietnam has been reported in recent literature—the prevalence rate was found to be 6.7% in a study of COPD in 12 Asian countries [8], while another study indicated that over half of those infected experienced exacerbation episodes [9]. Despite this, there has been a lack of research looking into the use of inhalers among Vietnamese COPD patients. This study aimed to examine the current situation regarding inhaler use technique and adherence in a cohort of COPD patients in Vietnam as well as factors potentially influencing such use, with a hope to identify implications and improve medication effectiveness.
2. Methods 2.1. Study Design and Participants
A cross-sectional, observational study was conducted at the Respiratory Center of Bach Mai hospital, a tertiary hospital in Northern Vietnam. We recruited 70 COPD patients that were hospitalized due to acute exacerbations of COPD (AECOPD) from September 2018 to October 2018. The inclusion criteria were: (1) Patients admitted to the Respiratory Center due to AECOPD; (2) patients currently using at least one inhaler device at home for COPD management; and (3) patients able to be interviewed having agreed to participate in the study. Patients who had an acute state of respiratory failure or severe mental illnesses were excluded. A convenient sampling method was adopted. A total of 70 patients participated in the study.
2.2. Data Collection and Outcome Assessment
We collected patient data from medical records to determine the eligibility of participants. Information about history of COPD, prescription of inhalers at home, and the length of hospitalization was also collected. Face-to-face interviews were conducted after patients stabilized the acute condition. We asked patients to demonstrate how they used their inhalers at home and to answer the 12-item Test of Adherence to Inhaler (TAI).
2.2.1. Inhaler Use Technique
Inhaler use technique was classified as poor and good according to the list of standards which were developed based on the 12-item TAI. We measured the use of metered-dose inhalers (MDI), soft-mist inhalers (SMI) and dry powder inhalers (DPI) among patients. Inhaler use technique was poor if the patients had any errors that might result in the loss of dose or reduction of drug delivery to the lung. Good inhaler use was defined as error-free. The items used to measure inhaler use are listed in Supplement S1.
2.2.2. Medication Adherence
We used the Vietnamese version of the TAI to assess patients’ level of adherence (Supplement S2). The TAI is a questionnaire that assesses the adherence among patients with asthma or COPD [10]. The 10-item TAI consists of 10 questions. The scoring range for each question is from 1 (worst compliance) to 5 (best compliance), resulting in a total score from 10 (minimum) to 50 (maximum). Patients were classified based on the score as follows:
1. 10-item scores equal or less than 45 (≤45): Poor adherence
2. 10-item scores from 46 to 49 (46–49): Intermediate adherence
3. 10-item scores of 50: Good adherence
Meanwhile, the 12-item TAI was used to explore non-adherence patterns. An additional two questions were used by the healthcare professionals, scoring from 1 (poor knowledge of the regimen and/or inhalation technique) to 2 (good knowledge). The types were categorized as below:
1. Items 1–5 score less than 25: “sporadic non-compliance” (<25)
2. Items 6–10 score less than 25: “deliberate non-compliance” (<25)
3. Items 11–12 score less than 4: “ignorant” non-compliance” (<4)
2.2.3. Assessment of Clinical Outcomes
Symptoms of COPD were also assessed using the Modified Medical Research Council scale of dyspnea (mMRC) grade ranging from 0–4 and the COPD Assessment Test (CAT) score ranging from 0–40. A higher CAT score means more severe symptoms.
2.3. Statistical Analysis
Data analysis was performed using SPSS software version 23.0 (SPSS Inc., Chicago, IL, USA) Descriptive statistics were adopted to examine patient characteristics. Generalized linear regression models, with binomial family and log link, were used to determine the associated factors with good/poor inhaler use and complete/not complete medication adherence. p-values less than 0.05 were considered statistically significant.
2.4. Ethical Approval
The purpose of the study was clearly explained to the participants and questionnaires were given to those who were willing to participate. The participants were informed that they had the right to withdraw at any time they wanted without any negative consequences to their current treatment. Patients’ information was kept secret. All information was encoded without revealing names and personal information. All participants provided written informed consents. The study protocol was approved by the Institutional Review Board of the Vietnam Respiratory Society (Code 03/QD-VNRS).
3. Results
Of the 70 participants, the mean age of patients was 68.6 (SD = 8.7) years old. The majority of patients were male (92.9%) and former smokers (82.9%). The mean number of pack-years was 31.1 ± 22.3 and the mean duration of COPD was 6.7 (SD = 7.5) years. According to GOLD 2017 classification, most patients were classified in group D (75.7%) (Table 1).
Table 2 shows that MDI users dominated the sample with 94.2%, followed by DPI and SMI users with 32.9% and 31.4%, respectively. Errors were more prevalent among MDI users compared to other groups. Full exhalation was the most common mistake at 72.8%, 69.6%, and 63.7% for MDI, DPI, and SMI, respectively. The proportion of patients with good inhaler technique in the MDI, DPI and SMI groups were 22.7%, 30.4% and 31.8%, respectively. Overall, 17 patients (24.3%) had good inhaler technique.
Table 3 reveals that 50% of the participants had poor adherence. The rates of non-compliance patterns for “Ignorant”, “sporadic”, and “deliberate” were 77.1%, 58.6%, and 55.7%, respectively.
The results of the multivariate regression models are shown in Table 4. People with a higher number of exacerbations in the last 12 months, higher CAT score and higher duration of hospitalization were less likely to have good inhaler technique. Meanwhile, those with a higher mMRC grade had a higher likelihood of having good inhaler technique (OR = 3.52; 95% CI = 1.22–10.12).
Regarding adherence, a higher CAT score was negatively associated with complete adherence (OR = 0.71; 95% CI = 0.58–0.87), while a higher duration of COPD was positively related to complete adherence (OR = 1.18; 95% CI = 1.02–1.36).
4. Discussion
Incorrect inhaler use technique and medication non-adherence were demonstrated to be associated with poor treatment outcomes among COPD patients. This study indicates that a large proportion of COPD patients use their inhalers incorrectly, of which most MDI users made errors in their use. Moreover, the current study reveals a significantly high rate of non-adherers in COPD patients. Incorrect inhaler use and poor adherence were found to be associated with high CAT scores, short durations of COPD, low mMRC grades, high durations of hospitalization and high numbers of exacerbations in the last 12 months.
In our cohort, a high percentage of patients making at least one error varied across the types of inhalers and steps, which is consistent with other studies [11,12]. Full exhalation is the leading error in all patients regardless of inhaler types, followed by inhalation and breath holding. These errors could be translated to mean that the patients were not fully aware of the technique that should be performed when using inhalers [13]. We also found that MDI users had more errors compared to other groups, which was similar to other previous findings. Batterink et al. found that patients using MDI experienced more errors than patients using other tools [14]. Al-Showair et al. reported that up to 60% of patients with COPD using MDI breathed too fast [15].
In this study, despite the importance of adherence in maximizing the therapeutic efficacy, optimal adherence was only observed in 30% of patients with AECOPD. This finding is significantly lower than previous studies in other clinical settings such as Australia (37–42%) [13,16], Hungary (58.2%) [17] and in seven Latin American countries (54.1%) [18]. Specifically, the prevalence of “ignorance type”, “erratic type”, and “deliberate type” of non-adherence were 77.1%, 60%, and 54.3% respectively, which is considerably higher than a study in Spain, which found that the prevalence of “ignorance”, “erratic”, and “deliberate” types were 31.2%, 47.8%, and 34.1%, correspondingly [19]. In terms of the “ignorance pattern”, most of the patients had poor knowledge of their own management of COPD, while for “erratic pattern” patients, we observed that the majority of patients stopped using their preventive inhaler due to “feeling healthy or the absence of severe symptoms”. Agh et al. also indicated that patients might be shown to stop treatment when no clinical symptoms appeared [17]. Regarding the “deliberate pattern” group, more than half of patients did not adhere to their preventive inhaler deliberately, mostly due to the financial burden of medication or traveling to a healthcare facility monthly to get medication.
Treatment adherence is a complex behavior that is affected by many factors [20]. Our results are consistent with previous studies showing that poor health outcomes (higher CAT scores, lower mMRC scores and more frequent exacerbations) and a high frequency of hospitalization were associated with inhaler mishandling and suboptimal adherence [13,16,20,21,22]. However, in the current study, we did not see an association between incorrect inhaler use technique and optimal adherence. Prior studies argued that treatment adherence and outcome were conversely influenced by inaccurate inhaler technique as well as multiple inhaler uses [20,23]. We supposed that a small sample size and a high level of homogeneity in our participants led to no significant association. Moreover, due to the complexity in predicting medication adherence in patients with COPD, the literature emphasizes that it is hard to fully identify the predictive factors within poor adherence practice [24], suggesting the involvement of multilevel factors regarding individual, family and societal perspectives in controlling treatment adherence.
Our findings suggest several implications. First, healthcare workers should provide clear instructions for patients and their families about the steps for inhaler use and underline important points that patients might forget or miss. Further, patients could perform the technique before the medical staff for correction. Second, health professionals should routinely check the inhaler usage of patients and counsel them appropriately and in a timely fashion. The literature shows that patients receiving inhalation instructions from healthcare workers have better technique than those who are self-studying [25]. Finally, further studies about the multilevel factors (individual, family and societal belief and perceived barriers) associated with medication adherence and inhaler use technique are warranted to fully support patients in managing and controlling COPD.
Limitations on this study included self-reported inhaler use technique and patient adherence, which might have led to recall bias as well as an over or under-estimation of medication utilization. In clinical practice, although self-reported measures are not more accurate than electronic monitoring, they provide a rapid and cheap assessment with acceptable results, playing a critical role in managing the disease. Selection bias due to the convenient sampling method might also have occurred. In addition, some clinical characteristics of patients such as spirometry results and bronchodilator responsiveness, which might be potentially associated with inhaler use technique and adherence, were not obtained. Moreover, the results might not reflect the pattern of non-adherence and inhaler use technique in other settings.
5. Conclusions
In conclusion, poor inhaler use and medication adherence were observed among patients with AECOPD in this study. Moreover, worse dyspnea, greater health condition impairment, and more frequent of exacerbations and hospitalizations were found to negatively affect correct inhaler use and treatment adherence. Instructions for COPD patients about using inhalers should focus on correct inhaler technique and adherence to preventive inhaled medication regimes even when feeling healthy.
Characteristics | n | % |
---|---|---|
Sex, Male | 65 | 92.9 |
Smoking status | ||
Current smoker | 7 | 10.0 |
Past smoker | 58 | 82.9 |
Never smoked | 5 | 7.1 |
Impact of symptoms (CAT score range) | ||
Low (<10) | 13 | 18.6 |
Medium (10–20) | 15 | 21.4 |
High (21–30) | 33 | 47.1 |
Very high (>30) | 9 | 12.9 |
mMRC grade | ||
Grade 0 | 2 | 2.9 |
Grade 1 | 11 | 15.7 |
Grade 2 | 11 | 15.7 |
Grade 3 | 34 | 48.6 |
Grade 4 | 12 | 17.1 |
GOLD 2017 classification | ||
A | 3 | 4.3 |
B | 6 | 8.6 |
C | 8 | 11.4 |
D | 53 | 75.7 |
Characteristics | Mean | SD |
Age | 68.6 | 8.7 |
Duration of COPD (years) | 6.7 | 7.5 |
Number of packs per year | 31.1 | 22.3 |
Number of exacerbations in the last 12 months | 2.4 | 2.1 |
Length of hospitalization | 9.7 | 4.7 |
CAT score | 20.1 | 8.5 |
CAT: COPD Assessment Test; mMRC: Modified Medical Research Council; COPD: chronic obstructive pulmonary disease.
Characteristics | MDI | DPI | SMI | |||
---|---|---|---|---|---|---|
n | % | n | % | n | % | |
Total | 66 | 94.2 | 23 | 32.9 | 22 | 31.4 |
Errors | ||||||
1. Prepare dose | 24 | 36.4 | 1 | 4.4 | 0 | 0.0 |
2. Full exhalation | 48 | 72.8 | 16 | 69.6 | 14 | 63.7 |
3. Inhalation | 25 | 37.9 | 8 | 34.8 | 2 | 9.1 |
4. Breath-holding | 23 | 34.9 | 6 | 26.1 | 6 | 27.3 |
5. Rinse mouth | 20 | 30.3 | 2 | 8.7 | - | - |
Good inhaler technique | 15 | 22.7 | 7 | 30.4 | 7 | 31.8 |
MDI: metered-dose inhalers; DPI: dry powder inhalers; SMI: soft-mist inhalers.
TAI Interpretation | n | % | |
---|---|---|---|
10-item score | Poor adherence (≤45) | 35 | 50.0% |
Intermediate adherence (46–49) | 14 | 20.0% | |
Good adherence (=50) | 21 | 30.0% | |
Item 1–5 score | Erratic pattern (<25) | 42 | 60.0% |
Non-erratic (=25) | 28 | 40.0% | |
Item 6–10 score | Deliberate pattern (<25) | 38 | 54.3% |
Non-deliberate (=25) | 32 | 45.7% | |
Item 11–12 score | Ignorance pattern (<4) | 54 | 77.1% |
Non-ignorant (=4) | 16 | 22.9% |
TAI: Test of Adherence to Inhaler.
Characteristics | Good Inhaler Technique | Complete Adherence | ||
---|---|---|---|---|
OR | 95% CI | OR | 95% CI | |
Age | 1.03 | 0.89; 1.19 | 1.05 | 0.94; 1.17 |
CAT score | 0.53 *** | 0.40; 0.71 | 0.71 *** | 0.58; 0.87 |
Duration of COPD | 1.09 | 0.79; 1.52 | 1.18 ** | 1.02; 1.36 |
GOLD level | 1.92 | 0.60; 6.11 | 0.79 | 0.30; 2.11 |
mMRC grade | 3.52 ** | 1.22; 10.12 | 2.00 | 0.79; 5.03 |
Number of packs per year | 0.96 * | 0.91; 1.00 | 1.01 | 0.98; 1.04 |
Current smoker (Yes/No) | 1.82 | 0.20; 16.66 | 0.14 * | 0.02; 1.38 |
Duration of hospitalization | 0.50 ** | 0.28; 0.88 | 0.93 | 0.76; 1.13 |
Number of exacerbations in the last 12 months | 0.05 *** | 0.01; 0.35 | 0.14 ** | 0.03; 0.70 |
Good inhaler technique (Yes/No) | 0.21 | 0.02; 2.39 |
CAT: COPD Assessment Test; mMRC: Modified Medical Research Council; COPD: chronic obstructive pulmonary disease; OR: Odds ratio; CI: Confident Interval. p < 0.1; ** p < 0.05; *** p < 0.01.
Supplementary Materials
The following are available online at https://www.mdpi.com/1660-4601/16/2/185/s1, Supplementary Materials S1: List of critical errors in inhalation technique, Supplementary Materials S2: 10-item and 12-item TAI questionnaire.
Author Contributions
Conceptualization, C.Q.N., D.M.P., G.V.V., H.T.C., P.T.P., P.N.D., G.T.V., L.H.N., G.H.H., T.H.T., B.X.T., C.A.L., C.S.H.H. and R.C.M.H.; Formal analysis, C.Q.N., D.M.P., G.V.V., H.T.C., P.T.P., P.N.D., G.T.V., L.H.N., G.H.H., B.X.T., C.A.L., C.S.H.H. and R.C.M.H.; Investigation, D.M.P., G.V.V., H.T.C., P.T.P., P.N.D.; Methodology, C.Q.N., D.M.P., G.V.V., H.T.C., P.T.P., P.N.D., G.T.V., L.H.N., G.H.H., B.X.T., C.A.L., C.S.H.H. and R.C.M.H.; Project administration, G.V.V., G.T.V. and L.H.N.; Writing-original draft, C.Q.N., D.M.P., G.V.V., H.T.C., P.T.P., P.N.D., G.T.V., L.H.N., G.H.H., T.H.T., B.X.T., C.A.L., C.S.H.H. and R.C.M.H.; Writing-review & editing, C.Q.N., G.V.V., H.T.C., G.T.V., L.H.N., G.H.H., B.X.T., C.A.L., C.S.H.H. and R.C.M.H.
Funding
This research received no external funding.
Acknowledgments
Our thanks to Respiratory Center of Bach Mai hospital that gave permission and support in conducting this study. We are grateful to all participant patients at the Respiratory Center who gave us their time to participate in this study.
Conflicts of Interest
No competing interests were disclosed.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
1. World Health Organization. Chronic Respiratory Diseases-Burden of COPD. Available online: http://www.who.int/respiratory/copd/burden/en/ (accessed on 1 December 2018).
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2019 Report. Available online: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf (accessed on 1 December 2018).
3. Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3, e442.
4. Molimard, M.; Colthorpe, P. Inhaler devices for chronic obstructive pulmonary disease: Insights from patients and healthcare practitioners. J. Aerosol. Med. Pulm. Drug Deliv. 2015, 28, 219-228.
5. Dougall, S.; Bolt, J.; Semchuk, W.; Winkel, T. Inhaler assessment in COPD patients: A primer for pharmacists. Can. Pharm. J. (Ott) 2016, 149, 268-273.
6. Price, D.; Keininger, D.L.; Viswanad, B.; Gasser, M.; Walda, S.; Gutzwiller, F.S. Factors associated with appropriate inhaler use in patients with COPD-Lessons from the REAL survey. Int. J. Chron. Obstruct. Pulm. Dis. 2018, 13, 695-702.
7. Yawn, B.P.; Colice, G.L.; Hodder, R. Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int. J. Chron. Obstruct. Pulm. Dis. 2012, 7, 495-502.
8. Regional, C.W.G. COPD prevalence in 12 Asia-Pacific countries and regions: Projections based on the COPD prevalence estimation model. Respirology 2003, 8, 192-198.
9. Lim, S.; Lam, D.C.; Muttalif, A.R.; Yunus, F.; Wongtim, S.; Lan le, T.T.; Shetty, V.; Chu, R.; Zheng, J.; Perng, D.W.; et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: The EPIC Asia population-based survey. Asia Pac. Fam. Med. 2015, 14, 4.
10. Plaza, V.; Fernández-Rodríguez, C.; Melero, C.; Cosío, B.G.; Entrenas, L.M.; de Llano, L.P.; Gutiérrez-Pereyra, F.; Tarragona, E.; Palomino, R.; López-Viña, A. Validation of the 'Test of the Adherence to Inhalers'(TAI) for Asthma and COPD Patients. J. Aerosol. Med. Pulm. Drug Deliv. 2016, 29, 142-152.
11. Arora, P.; Kumar, L.; Vohra, V.; Sarin, R.; Jaiswal, A.; Puri, M.M.; Rathee, D.; Chakraborty, P. Evaluating the technique of using inhalation device in COPD and bronchial asthma patients. Respir. Med. 2014, 108, 992-998.
12. Chorao, P.; Pereira, A.M.; Fonseca, J.A. Inhaler devices in asthma and COPD-An assessment of inhaler technique and patient preferences. Respir. Med. 2014, 108, 968-975.
13. Sriram, K.B.; Percival, M. Suboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patients. Chron. Respir. Dis. 2016, 13, 13-22.
14. Batterink, J.; Dahri, K.; Aulakh, A.; Rempel, C. Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease. Can. J. Hosp. Pharm. 2012, 65, 111.
15. Al-Showair, R.A.; Tarsin, W.Y.; Assi, K.H.; Pearson, S.B.; Chrystyn, H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir. Med. 2007, 101, 2395-2401. [Green Version]
16. George, J.; Kong, D.C.; Thoman, R.; Stewart, K. Factors associated with medication nonadherence in patients with COPD. Chest 2005, 128, 3198-3204.
17. Agh, T.; Inotai, A.; Meszaros, A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respir. Int. Rev. Thorac. Dis. 2011, 82, 328-334.
18. Montes de Oca, M.; Menezes, A.; Wehrmeister, F.C.; Lopez Varela, M.V.; Casas, A.; Ugalde, L.; Ramirez-Venegas, A.; Mendoza, L.; López, A.; Surmont, F.; et al. Adherence to inhaled therapies of COPD patients from seven Latin American countries: The LASSYC study. PLoS ONE 2017, 12, e0186777.
19. Plaza, V.; López-Viña, A.; Entrenas, L.M.; Fernández-Rodríguez, C.; Melero, C.; Pérez-Llano, L.; Gutiérrez-Pereyra, F.; Tarragona, E.; Palomino, R.; Cosio, B.G. Differences in adherence and non-adherence behaviour patterns to inhaler devices between COPD and asthma patients. COPD J. Chron. Obstruct. Pulm. Dis. 2016, 13, 547-554.
20. Sanduzzi, A.; Balbo, P.; Candoli, P.; Catapano, G.A.; Contini, P.; Mattei, A.; Puglisi, G.; Santoiemma, L.; Stanziola, A.A. COPD: Adherence to therapy. Multidiscip. Respir. Med. 2014, 9, 60.
21. Melani, A.S.; Bonavia, M.; Cilenti, V.; Cinti, C.; Lodi, M.; Martucci, P.; Serra, M.; Scichilone, N.; Sestini, P.; Aliani, M.; et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011, 105, 930-938. [Green Version]
22. Dalcin Pde, T.; Grutcki, D.M.; Laporte, P.P.; Lima, P.B.; Menegotto, S.M.; Pereira, R.P. Factors related to the incorrect use of inhalers by asthma patients. J. Bras. Pneumol. 2014, 40, 13-20. [Green Version]
23. Bosnic-Anticevich, S.; Chrystyn, H.; Costello, R.W.; Dolovich, M.B.; Fletcher, M.J.; Lavorini, F.; Rodriguez-Roisin, R.; Ryan, D.; Wan Yau Ming, S.; Price, D.B. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int. J. Chron. Obstruct. Pulm. Dis. 2017, 12, 59-71.
24. Hughes, C.M. Medication non-adherence in the elderly: How big is the problem? Drugs Aging 2004, 21, 793-811.
25. Pothirat, C.; Chaiwong, W.; Phetsuk, N.; Pisalthanapuna, S.; Chetsadaphan, N.; Choomuang, W. Evaluating inhaler use technique in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2015, 10, 1291. [Green Version]
1Department of Internal Medicine, Hanoi Medical University, Hanoi 100000, Vietnam
2Respiratory Center, Bach Mai Hospital, Hanoi 100000, Vietnam
3Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City 70000, Vietnam
4Center of Excellence in Evidence-Based Medicine, Nguyen Tat Thanh University, Ho Chi Minh City 70000, Vietnam
5Institute for Global Health Innovations, Duy Tan University, Da Nang 55000, Vietnam
6Department of Lower Limb Surgery, Vietnam-Germany Hospital, Hanoi 100000, Vietnam
7Institute for Preventive Medicine and Public Health, Hanoi Medical University, Hanoi 100000, Vietnam
8Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, MD 21205, USA
9Department of Psychological Medicine, National University Hospital, Singapore 119074, Singapore
10Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore
*Author to whom correspondence should be addressed.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
According to recent projections, COPD will become the third leading cause of death and the seventh leading cause of disability-adjusted life years (DALYs) worldwide by 2030, exhibiting a major increase in terms of mortality and DALY-caused rankings in 1990, which were sixth and twelfth, respectively [3]. Statistical Analysis Data analysis was performed using SPSS software version 23.0 (SPSS Inc., Chicago, IL, USA) Descriptive statistics were adopted to examine patient characteristics. According to GOLD 2017 classification, most patients were classified in group D (75.7%) (Table 1). [...]the current study reveals a significantly high rate of non-adherers in COPD patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer